


HF-POLARIS

zenagamtide | effects on heart failure outcomes in people with obesity

National Data Package



Japan

National Leader:




Koichiro Kuwahara

Participant overview

Participant overview	Overall recruitment target	Participants screened	Participants randomised	Screen failure rate*	Off treatment
	N	N	N	%	N
Japan	113	11	8	9	0
Global	5,610	1,064	438	46	12

*Forecasted

Participants randomised and recruitment target in Japan in 2026



Screen failure reasons

Screen failure reasons	Japan	Global*
	N (%)	N (%)
NT-proBNP (I7)	0 (0)	153 (38)
HF decompensation/ eGFR/UACR (I8)	0 (0)	104 (26)
Investigator discretion (E31)	0 (0)	22 (5)
HbA _{1c} >10% (E12)	0 (0)	12 (3)
LVEF (I5)	0 (0)	12 (3)
Diabetic retinopathy (E10)	0 (0)	10 (3)
ICF process (I1)	0 (0)	8 (2)
BMI (I3)	0 (0)	8 (2)
Malignancy history (E22)	0 (0)	7 (2)
Insulin therapy (E11)	0 (0)	6 (2)
Other	1 (100)	64 (16)

*Globally, 34 participants (13%) failed due to more than one eligibility criteria

BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA_{1c}, glycated haemoglobin; HF, heart failure; ICF, Informed Consent Form; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal B-type natriuretic peptide.

Site-level data



Planned number of sites: 32

Site*	PI	Participants, N			
		Screened	In screening	Screen failed	Randomised
3805	Akiyoshi Ogimoto	4	1	0	3
3807	Takeshi Arita	1	0	0	1
3808	Satoshi Shizuta	2	0	0	2
3811	Tomohiro Mita	1	0	0	1
3812	Yukio Hiroi	2	1	1	0
3823	Ken Umetani	1	0	0	1

*Only sites that have actively started recruitment are included

Notes



Notes

What are the challenges you face or anticipate facing concerning:



Recruitment?



Retention?



Collaboration with other stakeholders?

Are there any challenges in other areas that you'd like to address in your action plan?

What actions or initiatives can you implement to help resolve these issues?
